Max Chat
Share chart Biogen
Extended chart
Simple chart
About Biogen
Biogen Inc. — американская многонациональная биотехнологическая компания, базирующаяся в Кембридже, штат Массачусетс, специализирующаяся на открытии, разработке и поставке методов лечения нейродегенеративных, гематологических и аутоиммунных заболеваний пациентам во всем мире.
Main settings
IPO date
1991-09-16
ISIN
US09062X1037
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Див.доход ао
0
Дивиденд ао
22.23
Сайт
Grade
Underestimation
| Title | Value | Grade |
| P/S | 2.26 | 6 |
| P/BV | 1.31 | 9 |
| P/E | 13.43 | 8 |
Efficiency
| Title | Value | Grade |
| ROA | 5.95 | 2 |
| ROE | 10.36 | 4 |
| ROIC | 8.77 | 3 |
Dividends
| Title | Value | Grade |
| Dividend yield | 0 | 0 |
| DSI | 0.5 | 5 |
| Average dividend growth | 0 | 0 |
Debt
| Title | Value | Grade |
| Debt/EBITDA | 2.55 | 5 |
| Debt/Ratio | 0.2364 | 10 |
| Debt/Equity | 0.678 | 9 |
Growth impulse
| Title | Value | Grade |
| Yield Revenue, % | -28.01 | 0 |
| Yield Ebitda, % | -68.39 | 0 |
| Yield EPS, % | -54.89 | 0 |
Prices
| Price | Min. | Max. | Change | Changes in the industry | Changes in the index | |
| Yesterday | 133.19 $ | 0 $ | 0 $ | -0.24 % | 0 % | 0 % |
| Week | 126.92 $ | 0 $ | 0 $ | 4.69 % | 0 % | 0 % |
| Month | 131.86 $ | 124.76 $ | 133.19 $ | 0.77 % | 0 % | 0 % |
| Three month | 118.89 $ | 115.17 $ | 135.49 $ | 11.76 % | 0 % | 0 % |
| Half a year | 137.33 $ | 113.38 $ | 150.71 $ | -3.25 % | 0 % | 0 % |
| Year | 195.63 $ | 113.38 $ | 236.8 $ | -32.08 % | 0 % | 0 % |
| 3 years | 200.62 $ | 113.38 $ | 324.5 $ | -33.77 % | 0 % | 0 % |
| 5 years | 272.43 $ | 113.38 $ | 422.32 $ | -51.23 % | 0 % | 0 % |
| 10 years | 280.48 $ | 113.38 $ | 422.32 $ | -52.63 % | 0 % | 0 % |
| Year to date | 142.54 $ | 113.38 $ | 153.27 $ | -6.78 % | 0 % | 0 % |
Insider trading
| Insider | Transaction date | Date of disclosure | Type | Price | Volume | Quantity | Share before, % | Share after, % | Document |
| Izzar Rachid Officer |
08.07.2025 | 08.07.2025 | Purchase | 135 | 300 105 | 2223 | 0 | 0 | link |
| Gregory Ginger EVP, Human Resources |
07.02.2025 | 10.02.2025 | Purchase | 142.54 | 489 767 | 3436 | 0 | 0 | link |
| ALEXANDER SUSAN H EVP Chief Legal Officer |
07.02.2025 | 10.02.2025 | Purchase | 142.54 | 588 690 | 4130 | 0 | 0 | link |
| Singhal Priya Head of Development |
31.01.2025 | 03.02.2025 | Purchase | 143.93 | 263 104 | 1828 | 0 | 0 | link |
| Singhal Priya Head of Development |
12.02.2024 | 13.02.2024 | Sale | 239.45 | 100 330 | 419 | 0 | 0 | link |
| Izzar Rachid Head of Global Product Strat. |
09.02.2024 | 13.02.2024 | Purchase | 226.53 | 343 193 | 1515 | 0 | 0 | link |
| Kramer Robin Chief Accounting Officer |
09.02.2024 | 13.02.2024 | Purchase | 226.53 | 188 699 | 833 | 0 | 0 | link |
| MCDONNELL MICHAEL R EVP, Chief Financial Officer |
09.02.2024 | 13.02.2024 | Purchase | 226.53 | 737 808 | 3257 | 0 | 0 | link |
| Murphy Nicole Head of Pharm Ops and Tech |
09.02.2024 | 13.02.2024 | Purchase | 226.53 | 514 676 | 2272 | 0 | 0 | link |
| Singhal Priya Head of Development |
09.02.2024 | 13.02.2024 | Purchase | 226.53 | 274 554 | 1212 | 0 | 0 | link |
| Gregory Ginger EVP, Human Resources |
09.02.2024 | 13.02.2024 | Purchase | 226.53 | 488 852 | 2158 | 0 | 0 | link |
| Murphy Nicole Head of Pharm Ops and Tech |
08.02.2024 | 09.02.2024 | Purchase | 240.58 | 505 459 | 2101 | 0 | 0 | link |
| MCDONNELL MICHAEL R EVP, Chief Financial Officer |
08.02.2024 | 09.02.2024 | Purchase | 240.58 | 561 754 | 2335 | 0 | 0 | link |
| Kramer Robin Chief Accounting Officer |
08.02.2024 | 09.02.2024 | Purchase | 240.58 | 189 577 | 788 | 0 | 0 | link |
| Izzar Rachid Head of Global Product Strat. |
08.02.2024 | 09.02.2024 | Purchase | 240.58 | 491 505 | 2043 | 0 | 0 | link |
| Gregory Ginger EVP, Human Resources |
08.02.2024 | 09.02.2024 | Purchase | 240.58 | 393 348 | 1635 | 0 | 0 | link |
| ALEXANDER SUSAN H EVP Chief Legal Officer |
08.02.2024 | 09.02.2024 | Purchase | 240.58 | 526 870 | 2190 | 0 | 0 | link |
| Gregory Ginger EVP, Human Resources |
28.04.2023 | 02.05.2023 | Sale | 300 | 804 300 | 2681 | 0 | 0 | link |
| Kramer Robin Chief Accounting Officer |
08.12.2022 | 12.12.2022 | Purchase | 289.47 | 101 315 | 350 | 0 | 0 | link |
| ALEXANDER SUSAN H EVP Chief Legal Off & Corp Sec |
27.10.2022 | 28.10.2022 | Sale | 280.7 | 1 552 830 | 5532 | 0 | 0 | link |
| BIOGEN INC. 10% Owner |
30.08.2022 | 31.08.2022 | Sale | 5.27 | 527 000 | 100000 | 0 | -0.07 | link |
| BIOGEN INC. 10% Owner |
29.08.2022 | 31.08.2022 | Sale | 5.33 | 2 132 000 | 400000 | 0 | -0.27 | link |
| Izzar Rachid Head of Alzheimer's Disease |
01.07.2022 | 06.07.2022 | Purchase | 215.98 | 108 854 | 504 | 0 | 0 | link |
| Kramer Robin Chief Accounting Officer |
01.07.2022 | 06.07.2022 | Purchase | 215.98 | 54 427 | 252 | 0 | 0 | link |
| Guindo Chirfi Head of Glob Prod Strat & Com |
07.06.2021 | 09.06.2021 | Sale | 440 | 1 358 280 | 3087 | 0 | 0 | link |
| Sandrock Alfred Head of Research & Development |
07.06.2021 | 09.06.2021 | Sale | 440 | 3 375 680 | 7672 | 0 | 0 | link |
| Posner Brian S Director |
04.06.2021 | 07.06.2021 | Sale | 274.17 | 98 701 | 360 | 0 | 0 | link |
Main owners
| Institutions | Volume | Share, % |
| PRIMECAP Management Company | 16 264 481 | 11.19 |
| Vanguard Group Inc | 14 407 330 | 9.91 |
| Blackrock Inc. | 14 246 658 | 9.8 |
| State Street Corporation | 6 945 665 | 4.78 |
| T. Rowe Price Investment Management, Inc. | 5 357 326 | 3.69 |
| Wellington Management Group, LLP | 5 324 396 | 3.66 |
| JP Morgan Chase & Company | 5 011 319 | 3.45 |
| Geode Capital Management, LLC | 3 309 317 | 2.28 |
| Invesco Ltd. | 1 814 666 | 1.25 |
| ClearBridge Investments, LLC | 1 679 302 | 1.16 |
Contained in ETF
| ETF | Share, % | Profitability for 1 year, % | Commission, % |
| PSYK ETF | 4.07 | 0 | 0.75 |
| Future Tech ETF | 2.81727 | 479.5 | 0.35 |
| Principal Healthcare Innovators ETF | 2.81727 | -3.92 | 0.35 |
| IQ U.S. Mid Cap R&D Leaders ETF | 2.48 | 0 | 0.16 |
| John Hancock Multifactor Healthcare ETF | 2.34 | 29.34 | 0.40 |
| iShares Evolved U.S. Innovative Healthcare ETF | 2.29 | 0.000586 | 0.18 |
| Invesco S&P 500® Equal Weight Health Care ETF | 1.77 | 815.08 | 0.40 |
| Nationwide Maximum Diversification U.S. Core Equity ETF | 1.52 | 26.65 | 0.34 |
| IQ Engender Equality ETF | 1.05205 | 3.37 | 0.45 |
| Knowledge Leaders Developed World ETF | 0.91244 | -5.59 | 0.75 |
| JPMorgan Corporate Bond Research Enhanced ETF | 0.32 | -0.2672 | 0.09 |
| iShares Morningstar Mid-Cap ETF | 0.26833 | 245.03 | 0.04 |
| Nationwide Nasdaq-100 Risk-Managed Income ETF | 0.19851 | 7.59 | 0.68 |
| JPMorgan U.S. Aggregate Bond ETF | 0.18 | 0.5961 | 0.07 |
| iShares Morningstar Large-Cap Value ETF | 0.11151 | 51.43 | 0.25 |
| Columbia U.S. ESG Equity Income ETF | 0.10133 | -4.51 | 0.35 |
| iShares Morningstar Large-Cap ETF | 0.05802 | 186.3 | 0.03 |
Similar companies
P/E & P/BV
Company management
| Head | Job title | Payment | Year of birth |
| Ms. Robin C. Kramer | Senior VP & Chief Accounting Officer | N/A | 1966 (59 years) |
| Ms. Natacha Gassenbach | Chief Communication Officer & Head of Corporate Affairs | N/A | |
| Ms. Nicole Murphy | Head of Pharmaceutical Operations & Technology | 1.46M | 1973 (52 years) |
| Mr. Michael R. McDonnell CPA | Executive VP & CFO | 2.12M | 1964 (61 year) |
| Ms. Susan H. Alexander Esq. | Executive VP & Chief Legal Officer | 2.2M | 1957 (68 years) |
| Mr. Christopher A. Viehbacher | President, CEO & Director | 487.94k | 1961 (64 years) |
| Mr. Charles E. Triano | Senior VP & Head of Investor Relations | N/A | |
| Mr. Adam Keeney Ph.D. | Executive VP & Head of Corporate Development | N/A | 1977 (48 years) |
| Mr. Rachid Izzar | Head of Global Product Strategy & Commercialization | 1975 (50 years) | |
| Dr. Ginger Gregory Ph.D. | Executive VP & Chief Human Resources Officer | 1968 (57 years) |
About company
Address: United States, Cambridge, 225 Binney Street - Open in google maps, Open in yandex maps
Website: http://www.biogen.com
Website: http://www.biogen.com
